Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns

In conclusion, pembrolizumab achieves clinically meaningful survival benefits and an acceptable toxicity in PD-L1-positive advanced NSCLC. The high efficacy observed even in low PD-L1 expressers, and demographic differences in drug response, suggest that existing patient selection criteria could potentially be extended. These findings justify the application of a more advanced approach involving multiple biomarkers for more precise treatment allocation.